Haytaian Peter D
SEC CIK 1608538 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| ELV | Elevance Health | EVP, Pres, DBG, IngenioRx | 24.8K | — | $18.71M | 19 | 2021-11-01 | 2026-03-02 |
Most active insiders at ELV, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | BOUDREAUX GAIL | Pres, CEO, Dir | $1.00M | — |
| 2 | Kendrick Charles Morgan JR | EVP, Pres, Commercial | — | $910.6K |
| 3 | COLLIS STEVEN H | Dir | $869.5K | — |
| 4 | Penczek Ronald W | CAO, Ctrl | — | $766.0K |
| 5 | PERU RAMIRO G | Dir | $366.1K | — |
| 6 | Dixon Robert L JR | Dir | — | $60.7K |
| 7 | SCHULMAN AMY W | Dir | — | $7,475 |
| 8 | Wessling Erin M | EVP, CLO | — | — |
| 9 | Craig Ryan R | EVP, Chief HR Off | — | — |
| 10 | Kaye Mark | EVP, CFO | — | — |
| 15 | Haytaian Peter D | EVP, Pres Carelon, CarelonRx | — | — |
Transactions 19
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-04 | 2026-03-02 | ELV | Elevance Health | Haytaian Peter D | EVP, Pres Carelon, CarelonRx | A - Grant | $0.00 | +2,865 | 27.7K | +12% | $0 | |
| M | 2026-03-04 | 2026-03-02+ | ELV | Elevance Health | Haytaian Peter D | EVP, Pres Carelon, CarelonRx | F - Tax | $291.35 | -1,647 | 24.8K | -6% | -$479.9K |
| DM | 2025-03-05 | 2025-03-03 | ELV | Elevance Health | Haytaian Peter D | EVP, Pres Carelon, CarelonRx | A - Grant | $0.00 | +7,248 | 26.0K | +39% | $0 |
| D | 2025-03-05 | 2025-03-03 | ELV | Elevance Health | Haytaian Peter D | EVP, Pres Carelon, CarelonRx | F - Tax | $395.50 | -2,281 | 18.8K | -11% | -$902.1K |
| 2024-11-05 | 2024-11-01 | ELV | Elevance Health | Haytaian Peter D | EVP, Pres Carelon, CarelonRx | F - Tax | $414.01 | -1,649 | 17.2K | -9% | -$682.7K | |
| 2024-11-05 | 2024-11-01 | ELV | Elevance Health | Haytaian Peter D | EVP, Pres Carelon, CarelonRx | A - Grant | $0.00 | +3,799 | 21.0K | +22% | $0 | |
| DM | 2024-03-05 | 2024-03-01 | ELV | Elevance Health | Haytaian Peter D | EVP, Pres Carelon, CarelonRx | A - Grant | $0.00 | +11.6K | 25.0K | +86% | $0 |
| DM | 2024-03-05 | 2024-03-04 | ELV | Elevance Health | Haytaian Peter D | EVP, Pres Carelon, CarelonRx | S - Sale+OE | $500.18 | -21.1K | 35.8K | -37% | -$10.55M |
| D | 2024-03-05 | 2024-03-04 | ELV | Elevance Health | Haytaian Peter D | EVP, Pres Carelon, CarelonRx | M - OptEx | $166.97 | +15.0K | 40.0K | +60% | +$2.50M |
| D | 2024-03-05 | 2024-03-01 | ELV | Elevance Health | Haytaian Peter D | EVP, Pres Carelon, CarelonRx | F - Tax | $499.11 | -4,314 | 13.4K | -24% | -$2.15M |
| 2023-11-03 | 2023-11-01 | ELV | Elevance Health | Haytaian Peter D | EVP, Pres Carelon, CarelonRx | F - Tax | $446.66 | -154 | 17.7K | -0.9% | -$68.8K | |
| DM | 2023-03-03 | 2023-03-01+ | ELV | Elevance Health | Haytaian Peter D | EVP, Pres Carelon, CarelonRx | F - Tax | $468.80 | -6,076 | 11.4K | -35% | -$2.85M |
| DM | 2023-03-03 | 2023-03-01 | ELV | Elevance Health | Haytaian Peter D | EVP, Pres Carelon, CarelonRx | A - Grant | $0.00 | +12.0K | 23.4K | +106% | $0 |
| 2022-11-03 | 2022-11-01 | ELV | Elevance Health | Haytaian Peter D | EVP, Pres Carelon, IngenioRx | F - Tax | $544.53 | -200 | 12.0K | -2% | -$108.9K | |
| DM | 2022-03-14 | 2022-03-10 | ELV | Elevance Health | Haytaian Peter D | EVP, Pres, DBG, IngenioRx | S - Sale+OE | $460.71 | -17.7K | 23.4K | -43% | -$8.16M |
| D | 2022-03-14 | 2022-03-10 | ELV | Elevance Health | Haytaian Peter D | EVP, Pres, DBG, IngenioRx | M - OptEx | $131.80 | +1,848 | 29.9K | +7% | +$243.6K |
| DM | 2022-03-03 | 2022-03-01 | ELV | Elevance Health | Haytaian Peter D | EVP, Pres, DBG, IngenioRx | A - Grant | $0.00 | +10.5K | 20.3K | +107% | $0 |
| DM | 2022-03-03 | 2022-03-01+ | ELV | Elevance Health | Haytaian Peter D | EVP, Pres, DBG, IngenioRx | F - Tax | $452.65 | -5,160 | 28.0K | -16% | -$2.34M |
| D | 2021-11-03 | 2021-11-01 | ELV | Elevance Health | Haytaian Peter D | EVP, Pres, DBG, IngenioRx | A - Grant | $0.00 | +1,167 | 22.7K | +5% | $0 |
Purchase Sale Sale after option exercise All abbreviations